文献速递创伤与烧伤重症综合管理与镇静镇痛

氯胺酮用于创伤后急性疼痛:一项实用性随机临床试验

Ketamine for acute pain after trauma: A pragmatic, randomized clinical trial.
PubMed 文献 · J Trauma Acute Care Surg · 2024-05-01
一句话结论在口服多模式镇痛方案基础上加用亚解离剂量氯胺酮输注,可降低严重创伤患者的阿片类药物暴露,但谵妄发生率较高(11% vs 6%)。

本研究为实用性随机临床试验,纳入300例入住中间监护室或ICU的成人创伤患者,随机接受常规口服多模式镇痛方案(UC)或UC联合亚解离剂量氯胺酮输注24至72小时。主要终点为每日吗啡毫克当量(MME/d),氯胺酮组绝对减少7 MME/d,相对风险降低19%(RR 0.81,95%CI 0.69-0.95,贝叶斯后验概率pp=99%);总MME相对降低20%(RR 0.80,95%CI 0.64-0.99,pp=98%);出院带阿片类药物处方率相对降低8%(RR 0.92,95%CI 0.76-1.11,pp=81%)。氯胺酮组谵妄发生率较高(11% vs 6%),其他副作用如心律失常和计划外插管率相似。作者结论认为,亚解离剂量氯胺酮输注可作为在监护条件下减少阿片类药物暴露的安全辅助手段。

要点

  • 在口服多模式镇痛方案基础上加用亚解离剂量氯胺酮输注,可使创伤患者每日吗啡毫克当量绝对减少7 MME/d,相对降低19%(RR 0.81,95%CI 0.69-0.95,pp=99%)。
  • 氯胺酮组总吗啡毫克当量相对降低20%(RR 0.80,95%CI 0.64-0.99,pp=98%),出院带阿片类药物处方率相对降低8%(RR 0.92,95%CI 0.76-1.11,pp=81%)。
  • 氯胺酮组谵妄发生率较高(11% vs 6%),其他副作用如心律失常和计划外插管率两组相似。
  • 作者认为,亚解离剂量氯胺酮输注可作为在监护条件下减少阿片类药物暴露的安全辅助手段。
  • 研究证据等级为治疗/护理管理;Level I。

适用人群与场景

  • 纳入标准:入住中间监护室或重症监护室的成人创伤患者,入院时随机分组。

处置流程与药物剂量

  • 干预措施:在常规口服多模式镇痛方案基础上,加用亚解离剂量氯胺酮输注,持续24至72小时(自到达后开始)。
  • 对照措施:仅按本机构常规给予口服多模式镇痛方案。

研究设计与关键结果

  • 研究类型:实用性随机临床试验;样本量:最终分析300例(氯胺酮组144例,常规组156例);人群:入住中间监护室或ICU的成人创伤患者;干预:常规口服多模式镇痛方案联合亚解离剂量氯胺酮输注24至72小时 vs 常规口服多模式镇痛方案。
  • 基线特征:损伤严重度评分氯胺酮组19 [14, 29] vs 常规组22 [14, 29];长骨骨折率37% vs 49%;剖腹手术率16% vs 24%。
  • 主要终点:每日吗啡毫克当量(MME/d)绝对减少7 MME/d,相对风险降低19%(RR 0.81,95%CI 0.69-0.95,pp=99%)。
  • 次要终点:总MME绝对减少96,相对风险降低20%(RR 0.80,95%CI 0.64-0.99,pp=98%);出院带阿片类药物处方率绝对减少5%,相对风险降低8%(RR 0.92,95%CI 0.76-1.11,pp=81%)。
  • 不良事件:谵妄发生率氯胺酮组11% vs 常规组6%;心律失常和计划外插管率两组相似。

证据类型、等级与局限

  • 证据类型:实用性随机临床试验;证据等级:治疗/护理管理;Level I。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,亚解离剂量氯胺酮输注可作为在监护条件下减少阿片类药物暴露的安全辅助手段。
  • 适用人群:入住中间监护室或ICU的成人创伤患者;需在监护条件下使用。
  • 需注意谵妄发生率较高(11% vs 6%),其他副作用如心律失常和计划外插管率相似。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: Non-narcotic intravenous medications may be a beneficial adjunct to oral multimodal pain regimens (MMPRs) which reduce but do not eliminate opioid exposure and prescribing after trauma. We hypothesized that the addition of a subdissociative ketamine infusion (KI) to a standardized oral MMPR reduces inpatient opioid exposure.

METHODS: Eligible adult trauma patients admitted to the intermediate or intensive care unit were randomized upon admission to our institutional MMPR per usual care (UC) or UC plus subdissociative KI for 24 hours to 72 hours after arrival. The primary outcome was morphine milligram equivalents per day (MME/d) and secondary outcomes included total MME, discharge with an opioid prescription (OP%), and rates of ketamine side effects. Bayesian posterior probabilities (pp) were calculated using neutral priors.

RESULTS: A total of 300 patients were included in the final analysis with 144 randomized to KI and 156 to UC. Baseline characteristics were similar between groups. The Injury Severity Scores for KI were 19 [14, 29] versus UC 22 [14, 29]. The KI group had a lower rate of long-bone fracture (37% vs. 49%) and laparotomy (16% vs. 24%). Patients receiving KI had an absolute reduction of 7 MME/day, 96 total MME, and 5% in OP%. In addition, KI had a relative risk (RR) reduction of 19% in MME/day (RR, 0.81 [0.69-0.95], pp = 99%), 20% in total MME (RR, 0.80 [0.64-0.99], pp = 98%), and 8% in OP% (RR, 0.92 [0.76-1.11], pp = 81%). The KI group had a higher rate of delirium (11% vs. 6%); however, rates of other side effects such as arrythmias and unplanned intubations were similar between groups.

CONCLUSION: Addition of a subdissociative ketamine infusion to an oral MMPR resulted in a decrease in opioid exposure in severely injured patients. Subdissociative ketamine infusions can be used as a safe adjunct to decrease opioid exposure in monitored settings.

LEVEL OF EVIDENCE: Therapeutic/Care Management; Level I.

来源:J Trauma Acute Care Surg,查看原文。版权归原作者所有。

参考来源

  1. Klugh JM, Puzio TJ, Wandling MW, et al. Ketamine for acute pain after trauma: A pragmatic, randomized clinical trial. J Trauma Acute Care Surg. 2024. PMID: 38689402. doi:10.1097/TA.0000000000004325

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。